Northern Trust’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Northern Trust’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-512	Closed	-$30K	–	4431
2020 Q3	$30K	Buy	512 +34	+7%	+$3.04K	﹤0.01%	4163
2020 Q2	$62K	Buy	478 +26	+6%	+$2.3K	﹤0.01%	4019
2020 Q1	$26K	Hold	452	–	–	﹤0.01%	4057
2019 Q4	$57K	Buy	452 +151	+50%	+$20.4K	﹤0.01%	4033
2019 Q3	$36K	Hold	301	–	–	﹤0.01%	4091
2019 Q2	$90K	Hold	301	–	–	﹤0.01%	3991
2019 Q1	$135K	Hold	301	–	–	﹤0.01%	3857
2018 Q4	$138K	Hold	301	–	–	﹤0.01%	3860
2018 Q3	$274K	Sell	301 -6	-2%	-$3.96K	﹤0.01%	3785
2018 Q2	$180K	Buy	307 +17	+6%	+$11.1K	﹤0.01%	3888
2018 Q1	$189K	Buy	+290	New	+$218K	﹤0.01%	3844

Other funds holding HTGM

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Northern Trust's HTGM Position: Q4 2020 in Review

Northern Trust sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2020, closing a stake of 512 shares — an estimated $30K sold.

Northern Trust first reported a position in HTGM in Q1 2018 and held it in 11 quarters. The position peaked at $274K in Q3 2018. 23 funds tracked by Wall St. Rank hold HTGM as of Q4 2020.

Northern Trust reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Northern Trust sold 512 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2020, an estimated $30K.
Northern Trust first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 11 quarters.
Northern Trust's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $274K in Q3 2018.
23 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2020.

Based on Northern Trust's 13F filing for Q4 2020, filed 11 Feb 2021.